Key result
Two cases of severe short stature initially treated with recombinant human growth hormone were eventually diagnosed with Laron syndrome and initiated on rhIGF-1 therapy.
Why the study?
Laron syndrome is clinically indistinguishable from growth hormone deficiency in most circumstances, but differentiating them is essential because treatments are different, expensive, and prolonged.
Case Report (n=2)
Differentiating Laron syndrome from growth hormone deficiency is crucial to initiate appropriate therapy with rhIGF-1.
May prompt IGF-1 assessment in rhGH-refractory short stature; leaves open optimal diagnostic algorithms for Laron syndrome.
Laron syndrome or growth hormone insensitivity is a rare disease presenting with severe postnatal growth failure. Clinically, in most circumstances, it is indistinguishable from growth hormone deficiency. Differentiating between the two conditions is important because the treatment modalities are different, expensive, and prolonged. Here, we share our experience with two cases of severe short stature who were initially diagnosed with growth hormone deficiency and both were treated with recombinant human growth hormone. However, eventually they were diagnosed with growth hormone insensitivity or Laron syndrome and initiated on recombinant human insulin like growth factor-1 (rhIGF-1) therapy.
No takes yet. Share an insight, caveat, or question.
Boro et al. (2020) conducted a case report in Laron syndrome (n=2). recombinant human insulin like growth factor-1 (rhIGF-1) vs. recombinant human growth hormone (initial misdiagnosis treatment) was evaluated. Two cases of severe short stature initially treated with recombinant human growth hormone were eventually diagnosed with Laron syndrome and initiated on rhIGF-1 therapy.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: